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Background and Purpose: Zonisamide (ZNS) is a useful antiepileptic drug with a broad therapeutic spectrum. 
However, there is limited information on the long-term use of ZNS as a monotherapy. This study investigated the 
long-term effects of ZNS as a monotherapy for the treatment of epilepsy.
Methods: We retrospectively analyzed the records of epilepsy patients treated with ZNS monotherapy at our clinic. 
We identified outcomes for patients treated with ZNS monotherapy for a minimum of 6 months. Efficacy was 
quantified as the percentage change in seizure frequency, and safety was assessed by the frequency and types of 
adverse events.
Results: Sixty patients who received ZNS for a minimum of 6 months were included. The mean duration of 
treatment was 19.8 months (range, 6-37 months), and the mean ZNS dosage was 255 mg/day (range, 100-500 
mg/day). Twenty-seven patients (45%) were seizure-free, and an additional 20 patients (33%) had above 50% 
seizure frequency reduction at the last follow-up visit. Partial seizures with or without secondary generalization and 
generalized seizures were well controlled by ZNS, whereas complex partial seizures were not. Forty-eight patients 
(80%) reported mild-to-moderate adverse events, including memory loss (35%), attention deficit (27%), and weight 
loss (20%).
Conclusions: Long-term ZNS monotherapy is effective at treating a broad spectrum of seizure disorders, except 
complex partial seizures. However, a specific adverse event, such as cognitive impairment, is common and 
long-lasting.
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INTRODUCTION
Zonisamide (ZNS, Exegran
®) has been shown to 
be a useful antiepileptic drug (AED) with a broad 
therapeutic spectrum.
1-3 It has been used in Japan 
since 1989, and is effective against simple and complex 
partial seizures, generalized tonic-clonic seizures (GTCS), 
myoclonic epilepsies, Lennox-Gastaut syndrome, and 
infantile spasms.
4 ZNS was introduced into the South 
Korean market in June 1992, and subsequently approved 
as a monotherapy. Recently, ZNS mono- or add-on 
therapy (100–1100 mg/day) was shown to be a safe, 
effective, and well-tolerated long-term treatment option 
in pediatric and adult epilepsy patients.
5-12  Among 
them, 26-61% of patients reported mild-to-moderate 
adverse events, and the severity of these events tended 
to decrease over time, suggesting that patients develop 
a tolerance to them.
10
During the period of introduction of ZNS into the Journal of Clinical Neurology: Vol. 3, No. 4, 2007
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Korean market, several studies evaluated its efficacy 
and safety in epilepsy patients.
13-17 Patients received 
ZNS dosages ranging from 100 to 600 mg/day for 
periods from 2 to 15 months. Seizure freedom occurred 
in 0-30% of patients, and a seizure frequency reduction 
of  ≥50% was demonstrated in 55-83% of patients. 
Mild-to-moderate adverse events such as gastrointestinal 
troubles, dizziness, somnolence, weight loss, and head-
ache were detected in 35-69% of patients. Although 
these studies have provided information about the 
usefulness of ZNS in epilepsy patients, they did not 
provide any information about the effectiveness of 
long-term ZNS monotherapy in newly diagnosed 
epilepsy, because the majority of studies considered 
only the short-term (≤6 months) effectiveness of 
ZNS as an add-on therapy for intractable epilepsy. 
More recently, a double-blind, randomized, comparative 
study of ZNS and carbamazepine (CBZ) as a mono-
therapy in newly diagnosed epilepsy was conducted 
by the Korean ZNS Group.
18 The 24-week remission 
rate of seizures with 302 mg/day ZNS was 69.9%, 
which was similar to that of 611 mg/day CBZ. The 
mean time to the first seizure recurrence in the ZNS 
group was 41 days, which was also similar to that 
of CBZ group. Although the profiles of adverse 
events differed between ZNS and CBZ, the incidence 
of these events did not differ significantly between 
the two groups (67.1% and 53.7%, respectively). 
Although that study concluded that ZNS was as 
effective and safe as CBZ as a 6-month therapy, it 
did not elucidate the long-term effectiveness of ZNS 
monotherapy.
In the current study, we evaluated the efficacy and 
safety of long-term treatment with ZNS as a mono-
therapy (6-37 months) by reviewing charts of 60 
patients treated at our epilepsy clinic.
MATERIALS AND METHODS
A retrospective chart review was conducted to 
identify outcomes for patients with epilepsy who had 
received long-term ZNS monotherapy (≥6 months) in 
our epilepsy clinic between January 2000 and June 
2007. ZNS monotherapy was applied to patients with 
either newly diagnosed epilepsy or formerly diagnosed 
epilepsy who were not treated at clinic visits.
The efficacy of ZNS was quantified using the 
baseline seizure frequency for 3 months before therapy 
and compared with seizure frequency for the same 
period at the end of treatment, defined as: seizure 
freedom,  ≥75% reduction, ≥50% reduction, ＜50% 
reduction, or no effect. The response rate of ZNS on 
seizure was calculated by the frequency of patients 
with  ≥50% seizure frequency reduction among all 
patients. Patients who discontinued ZNS treatment 
before 6 months or whose seizure response data 
were unavailable were not included in the efficacy 
analyses. The frequencies and types of adverse events 
were recorded to assess the safety of ZNS. In order 
to assess changes in adverse events over time, we 
compared the frequency of adverse events before 6 
months (a short-term treatment) with that after 6 
months of medication (a long-term treatment). The 
seizure frequency and side effects, as reported by the 
patients, were recorded by a physician at follow-up 
clinic visits.
RESULTS
1. Demographic and treatment data
The chart review revealed that 100 patients had 
been treated with ZNS monotherapy, of which 40 
(40%) were excluded from the study due to their 
ZNS intake lasting less than 6 months. The reasons 
for incomplete medication were adverse events in 12 
patients (12%), inefficacy in 10 patients (10%), spon-
taneous off-medication without specific reasons in 3 
patients (3%), follow-up loss in 2 patients (2%), and 
a ZNS intake lasting less than 6 months at the time 
of chart review in 13 patients (13%). The disconti-
nuation of treatment was due to cognitive dysfunction 
in four patients (4%). Therefore, 60 patients were 
included in the study.
The characteristics of epilepsy patients who received 
ZNS for a minimum of 6 months are listed in Table 1. Park SP, et al. Zonisamide Monotherapy in Epilepsy Patients
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Table 1. Characteristics of epilepsy patients receiving 
zonisamide for a minimum of 6 months (n=60)
Characteristics
Age, years, mean (range) 29.8 (16-65)
Sex, % male 60
Seizure type, % 
Partial 7
Complex partial 27
Secondarily generalized 23
Generalized 43
Duration of epilepsy, years, mean 
(range)
2.5 (0.1-12)
Newly diagnosed epilepsy, % 87
Zonisamide dose at last visit, mg/day, 
mean (range)
255.0 (100-500)
Duration of medication, months, mean 
(range)
19.8 (6-37)
Figure 1. Efficacy of zonisamide monotherapy. The per-
centage reduction in seizure frequency from baseline to the 
end of the treatment period was measured in 60 patients. 
Seizure freedom occurred in 45% of patients, and the 
reduction of seizure frequency by ≥50% was observed 
in 78% of patients.
 Simple partial (n=4)     Complex partial        Secondarily        Generalized (n=26)
                               (n=16)         generalized (n=14)
Seizure type
Figure 2. Efficacy of zonisamide monotherapy against 
various seizure types. All seizure types except 
complex partial seizure were well controlled by 
zonisamide. Seventy-seven percent of patients with 
idiopathic generalized epilepsy became seizure-free 
with zonisamide.
Their mean age was 29.8 years (range, 16-65 years).
Similar proportions of patients experienced partial 
seizures and generalized seizures. Among 26 patients 
(43%) with generalized seizures, 20 patients were 
diagnosed as GTCS only and 6 patients as juvenile 
myoclonic epilepsy (JME). The proportion of patients 
with newly diagnosed epilepsy was 87%. The mean 
daily ZNS dosage at the last visit was 255 mg 
(range, 100-500 mg), and the mean duration of therapy 
was 19.8 months (range, 6-37 months).
2. Efficacy profile
The efficacy of ZNS monotherapy ranged from 
seizure freedom to no effect, as shown in Figure 1. 
Among the 60 patients, 27 patients (45%) became 
seizure-free, and the seizure frequency reduced by ≥
50% was demonstrated in an additional 20 patients 
(33%). The response rate to ZNS was 78%. However, 
five patients (8%) had a poor response to ZNS 
(reduction in seizure frequency of <50%), and eight 
patients (13%) experienced no change in seizure 
frequency. The efficacy of ZNS monotherapy against 
various seizure types is shown in Figure 2. The 
seizure-free rates for simple partial seizures, complex Journal of Clinical Neurology: Vol. 3, No. 4, 2007
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Table 2. Adverse events with zonisamide according to 
duration of treatment (n=60)
n (%)
Adverse event < 6 months* ≥ 6 months
†
Somnolence 26 (43)  6 (10)
Memory loss 24 (40) 21 (35)
Attention deficit 17 (28) 16 (27)
Headache 16 (27)  6 (10)
Dizziness 14 (23) 2 (3)
Weight loss 15 (25) 12 (20)
Language problems 10 (17)  9 (15)
Fatigue  8 (13) 0 (0)
Insomnia  9 (15)  6 (10)
Gastrointestinal symptoms  8 (13) 1 (2)
Nervousness  7 (12) 5 (8)
Anxiety 2 (3) 2 (3)
Depression 2 (3) 1 (2)
Dyscalculia 2 (3) 2 (3)
Weight gain 1 (2) 1 (2)
*During the short-term treatment, 54 of patients (90%) 
reported adverse events.
†During the long-term treatment, 48 of patients (80%) 
reported adverse events.
partial seizures, partial seizures with secondary 
generalization, and generalized seizures were 75%, 
0%, 29%, and 77%, respectively. All JME patients 
(n=6) were seizure-free for a mean of 23 months 
(range, 12-34 months). The response rates of partial 
seizures with or without secondary generalization 
and generalized seizures were excellent (86-100%), 
whereas that of complex partial seizures was not 
(44%).
3. Safety profile
Adverse events that occurred with ZNS mono-
therapy are listed in Table 2. Forty-eight patients 
(80%) reported mild-to-moderate adverse events 
during long-term treatment (≥6 months), the most 
frequent of which were memory loss (35%), attention 
deficit (27%), and weight loss (20%). Fifty-four patients 
(90%) reported adverse events during short-term treat-
ment (<6 months), the most frequent of which were 
somnolence (43%), memory loss (40%), and attention 
deficit (28%). The frequency of CNS symptoms such 
as somnolence, headache, dizziness, and fatigue 
decreased dramatically after 6 months of treatment, 
with that of cognitive dysfunction and weight loss 
decreasing less.
DISCUSSION
This chart-review study supports previous findings 
on the efficacy of ZNS as a long-term monotherapy 
for various seizure types. With a mean ZNS treatment 
duration of 20 months, more than 70% of patients 
experienced seizure control for simple partial seizures 
with or without secondary generalization and generalized 
seizures, with the seizure-free rate being high for 
generalized seizures including JME. However, despite 
its efficacy, there was a high incidence of adverse 
events during ZNS medication. Cognitive impairment 
was a common adverse event, and this had not dis-
appeared even after 6 months of treatment.
Recently, ZNS monotherapy (100-1000 mg/day) 
for durations from 2 weeks to 180 months was found 
to be a safe, effective, and well-tolerated treatment 
option in pediatric and adult epilepsy patients.
5-8,11,12 
Seizure freedom occurred in 24-56% of patients, and 
a seizure frequency reduction of ≥50% was demon-
strated in 64-77% of patients. All seizure types responded 
well to ZNS monotherapy. The seizure-free rates 
among patients with complex partial seizures and 
generalized seizures were 44-62% and 34-53%, 
respectively. The efficacy profile of JME was not 
described. Our results for the seizure-free and 
response rates were similar to these previously reported 
results, except that no seizure freedom occurred in 
complex partial seizures and the seizure-free rate was 
higher (77%) in generalized seizures. A prospective, 
observational study of 1,102 adults with symptomatic, 
localization-related epilepsy found that standard AED 
therapy resulted in 21-28% of patients with complex 
partial seizures being seizure-free at 12 months.
19 In 
contrast, none of our patients were seizure-free with 
ZNS therapy. Since the seizure-free rate can vary 
with the underlying etiology, AED therapy, or even 
follow-up duration, future large population studies 
should attempt to elucidate the efficacy of ZNS Park SP, et al. Zonisamide Monotherapy in Epilepsy Patients
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against complex partial seizures. All of our JME 
patients (n=6) achieved seizure freedom for almost 2 
years. Although valproate has been recommended for 
the treatment of JME, a recent study found that 80% 
of patients on ZNS monotherapy showed ≥50% 
reduction in seizure frequency for 1 year.
20  Despite the 
likelihood of ZNS being effective against generalized 
seizures, previous long-term studies were open-label 
and retrospective, and had investigated a small number 
of patients, and case selection bias could have been 
present. Therefore, further studies including larger 
numbers of patients are needed to clarify the true 
efficacy of ZNS monotherapy against specific seizure 
or epilepsy types.
The reported incidence of adverse events with ZNS 
monotherapy is 5-33%.
5–8,11,12 ZNS was well tolerated 
and associated with only mild-to-moderate adverse 
events. In a postmarketing surveillance study of more 
than 1,000 patients treated for 1-3 years, the most 
common adverse events included mental/psychic, 
gastrointestinal, and neurological symptoms.
6 Cognitive 
dysfunction has been reported in 1-17% of patients.
5-8,11 
Adverse events that may lead to discontinuation are 
most likely to occur within the first 3 months of 
treatment.
5,6,8 The severity of adverse events tends to 
decrease over time, suggesting that patients develop 
a tolerance to them.
6,8,10 In contrast, we found a 
much higher incidence of adverse events (80%) even 
after 6 months of treatment. Although most of the 
adverse events were mild or moderate, the incidence 
of cognitive dysfunction such as memory loss (35%) 
and attention deficit (27%) was high. Compared to 
adverse events of short-term treatment, the frequency 
of CNS symptoms such as somnolence, headache, 
dizziness, and fatigue decreased during long-term 
treatment. However, the frequency of cognitive dys-
function decreased less. These observations may 
indicate that cognitive dysfunction induced by ZNS 
treatment will not be tolerated over a longer period. 
There are several possible reasons for the discre-
pancies in the frequencies of cognitive complaints 
between our study and previous studies. First, the 
dosage requirements and the potential for toxic 
reactions to psychotropic medication might differ 
between racial and ethnic groups.
21 However, since 
the frequency of cognitive dysfunction in many 
Japanese studies was much lower than that of our 
study, it is impossible to deduce that the cognitive 
impairment is solely due to ethnic variations. Second, 
ZNS patients in previous trials may have had poor 
awareness of their cognitive dysfunction and they 
may not have reported these problems spontaneously. 
The lack of awareness of a cognitive deficit might 
be influenced by personality factors, perhaps aug-
mented by the stress involved in a chronic condition.
22 
Therefore, specific questioning about cognitive problems 
and brief cognitive testing during clinic visits by 
patients may be particularly important when managing 
patients receiving AEDs. Third, psychosocial factors 
such as depression or anxiety may affect epilepsy 
patients, and mood disorders are known to independently 
compromise the integrity of memory processing.
23 
Furthermore, epilepsy patients who have mood disorders 
tend to overstate memory problems.
22 Although the 
incidence of mood complaints was trivial in our 
study, both events may increase cognitive complaints.
In conclusion, long-term ZNS monotherapy is 
effective at treating a broad spectrum of seizure 
disorders, except complex partial seizures. However, 
a specific adverse event, such as cognitive impair-
ment, is common and long-lasting. Cognitive effects 
are only one factor in AED selection, with it being 
possible that the risks of cognitive dysfunction are 
outweighed by the potential for seizure control and 
overall improvement in the quality of life in particular 
patients. Even though our patients showed cognitive 
dysfunction associated with ZNS, they continued to 
take the medicine due to its efficacy. However, the 
ultimate goal for epilepsy treatment is to choose the 
AED that best controls the patient’s seizures with the 
fewest side effects. Cognitive function exerts important 
effects on the quality of life in younger patients who 
are more affected by academic or occupational func-
tioning. Therefore, further objective studies such as 
neuropsychological or neuroimaging investigations 
are needed to clarify the effect of ZNS on cognition. 
Moreover, the optimal target dose of ZNS mono-
therapy should be determined to minimize dose-related Journal of Clinical Neurology: Vol. 3, No. 4, 2007
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adverse events.
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